[1]
|
黄晓军, 吴德沛, 刘代红. 实用造血干细胞移植[M]. 第2版. 北京: 人民卫生出版社, 2019.
|
[2]
|
宋铁梅, 陈广华, 张翔, 等. 异基因造血干细胞移植后CMV与EBV共激活患者临床预后分析[J]. 中华医学杂志, 2014(40): 3135-3139.
|
[3]
|
崔东艳, 张杰, 张桥, 等. 巨细胞病毒感染对骨髓造血细胞的免疫损伤作用[J]. 中华医学杂志, 2019, 99(22): 1727-1730.
|
[4]
|
Chang, Y.-J., Wu, D.-P., Lai, Y.-R., et al. (2020) Antithymocyte Globulin for Matched Sibling Donor Transplantation in Patients with Hematologic Malignancies: A Multicenter, Open-Label, Randomized Controlled Study. Journal of Clinical Oncology, 38, 3367-3376. https://doi.org/10.1200/JCO.20.00150
|
[5]
|
Zhang, Y.-Y., Mo, W.-J., Zuo, Y.-Y., et al. (2020) Comparable Survival Outcome Between Transplantation from Haploidentical Donor and Matched Related Donor or Unrelated Donor for Severe Aplastic Anemia Patients Aged 40 Years and Older: A Retrospective Multicenter Cohort Study. Clinical Transplantation, 34, e13810.
https://doi.org/10.1111/ctr.13810
|
[6]
|
Chang, Y.-J., Wang, Y., Xu, L.-P., et al. (2020) Haploidentical Donor Is Preferred over Matched Sibling Donor for Pre-Transplantation MRD Positive ALL: A Phase 3 Genetically Randomized Study. Journal of Hematology & Oncology, 13, Article No. 27. https://doi.org/10.1186/s13045-020-00860-y
|
[7]
|
Gao, X.-N., Lin, J., Wang, L.-J., et al. (2020) Risk Factors and Associations with Clinical Outcomes of Cytomegalovirus Reactivation after Haploidentical versus Matched-Sibling Un-manipulated PBSCT in Patients with Hematologic Malignancies. Annals of Hematology, 99, 1883-1893. https://doi.org/10.1007/s00277-020-04156-6
|
[8]
|
Yeh, T.-J., Yang, C.-I., Huang, C.-T., et al. (2022) Revisit of the Association between Cytomegalovirus Infection and Invasive Fungal Infection after Allogeneic Hematopoietic Stem Cell Transplantation: A Real-World Analysis from a High CMV Seroprevalence Area. Journal of Fungi, 8, Article No. 408. https://doi.org/10.3390/jof8040408
|
[9]
|
Dong, M.Y., Tang, B.L., Zhu, X.Y., et al. (2020) Protective Effects of Cytomegalovirus DNA Copies ≧ 1000/mL for AML Patients in Complete Remission after Single Cord Blood Trans-plantation. Infection and Drug Resistance, 13, 373-383. https://doi.org/10.2147/IDR.S225465
|
[10]
|
Tong, J., Sun, Z., Liu, H., et al. (2013) Risk Factors of CMV Infection in Patients after Umbilical Cord Blood Transplantation: A Mul-ticenter Study in China. Chinese Journal of Cancer Research, 25, 695-703.
|
[11]
|
Zhao, C., Zhao, X.-S., Xu, L.-P., et al. (2022) Recipient and Donor PTX3 rs2305619 Polymorphisms Increase the Susceptibility to Invasive Fungal Disease Following Haploidentical Stem Cell Transplantation: A Prospective Study. BMC Infectious Diseases, 22, Article No. 292. https://doi.org/10.1186/s12879-022-07298-2
|
[12]
|
Chen, Y., Xu, L.-P., Liu, K.-Y., et al. (2016) Risk Factors for Cytomegalovirus DNAemia Following Haploidentical Stem Cell Transplantation and Its Association with Host Hepatitis B Virus Serostatus. Journal of Clinical Virology, 75, 10-15. https://doi.org/10.1016/j.jcv.2015.12.003
|
[13]
|
Lin, R., Wang, Y., Huang, F., et al. (2019) Two Dose Levels of Rabbit Antithymocyte Globulin as Graft-versus-Host Disease Prophylaxis in Haploidentical Stem Cell Transplantation: A Multicenter Randomized Study. BMC Medicine, 17, Article No. 156. https://doi.org/10.1186/s12916-019-1393-7
|
[14]
|
Massoud, R., Gagelmann, N., Fritzsche-Friedland, U., et al. (2022) Comparison of Immune Reconstitution between Anti-T-Lymphocyte Globulin and Posttransplant Cyclophos-phamide as Acute Graft-versus-Host Disease Prophylaxis in Allogeneic Myeloablative Peripheral Blood Stem Cell Transplantation. Haematologica, 107, 857-867.
https://doi.org/10.3324/haematol.2020.271445
|
[15]
|
Hakki, M., Aitken, S.L., Danziger-Isakov, L., et al. (2021) American Society for Transplantation and Cellular Therapy Series: #3—Prevention of Cytomegalovirus Infection and Disease after Hematopoietic Cell Transplantation. Transplantation and Cellular Therapy, 27, 707-719. https://doi.org/10.1016/j.jtct.2021.05.001
|
[16]
|
Solano, C., Vazquez, L., Gimenez, E., et al. (2021) Cytomegalovirus DNAemia and Risk of Mortality in Allogeneic Hematopoietic Stem Cell Transplantation: Analysis from the Spanish Hematopoietic Transplantation and Cell Therapy Group. American Journal of Transplantation, 21, 258-271. https://doi.org/10.1111/ajt.16147
|
[17]
|
Xuan, L., Huang, F., Fan, Z., et al. (2012) Effects of Intensified Condition-ing on Epstein-Barr Virus and Cytomegalovirus Infections in Allogeneic Hematopoietic Stem Cell Transplantation for Hematological Malignancies. Journal of Hematology & Oncology, 5, Article No. 46. https://doi.org/10.1186/1756-8722-5-46
|
[18]
|
Goldsmith, S.R., Abid, M.B., Auletta, J.J., Bashey, A., Beitinjaneh, A., Castillo, P., Chemaly, R.F., Chen, M., Ciurea, S., Dandoy, C.E., Díaz, M.Á., Fuchs, E., Ganguly, S., Kanakry, C.G., Kanakry, J.A., Kim, S., Komanduri, K.V., Krem, M.M., Lazarus, H.M., Liu, H., Ljungman, P., et al. (2021) Posttrans-plant cyclophosphamide Is Associated with Increased Cytomegalovirus Infection: A CIBMTR Analysis. Blood, 137, 3291-3305.
https://doi.org/10.1182/blood.2020009362
|
[19]
|
Green, M.L., Leisenring, W., Xie, H., et al. (2016) Cytomegalovi-rus Viral Load and Mortality after Haemopoietic Stem Cell Transplantation in the Era of Pre-Emptive Therapy: A Retro-spective Cohort Study. The Lancet Haematology, 3, e119-e127. https://doi.org/10.1016/S2352-3026(15)00289-6
|
[20]
|
Arcuri, L.J., et al. (2020) Impact of Anti-CMV IgG Titers and CD34 Count Prior to Hematopoietic Stem Cell Transplantation from Alternative Donors on CMV reactivation. Biol-ogy of Blood and Marrow Transplantation, 26, e275-e279. https://doi.org/10.1016/j.bbmt.2020.07.034
|
[21]
|
刘静, 付强, 王昱, 等. 供者巨细胞病毒血清学阴性状态对异基因造血干细胞移植患者预后影响的临床分析[J]. 中华内科杂志, 2021, 60(5): 459-465.
|
[22]
|
戴文露, 李春雨, 高艳林, 等. 供者CMV和EBV血清学状态对异基因造血干细胞移植患者临床预后的影响[J]. 临床血液学杂志, 2022, 35(7): 479-485.
|
[23]
|
Czerw, T., Labopin, M., Schmid, C., Cornelissen, J.J., Chevallier, P., Blaise, D., et al. (2016) High CD3+ and CD34+ Peripheral Blood Stem Cell Grafts Content Is Associated with Increased Risk of Graft-versus-Host Disease without Beneficial Effect on Disease Control after Reducedintensity Conditioning Allogeneic Transplantation from Matched Unrelated Donors for Acute Myeloid Leukemia—An Analysis from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation. Oncotarget, 7, 27255-27266.
https://doi.org/10.18632/oncotarget.8463
|
[24]
|
Yokoyama, Y., Maie, K., Fukuda, T., et al. (2020) A High CD34+ Cell Dose Is Associated with Better Disease-Free Survival in Patients with Low-Risk Diseases Undergoing Peripheral Blood Stem Cell Transplantation from HLA-Matched Related Donors. Bone Marrow Transplantation, 55, 1726-1735. https://doi.org/10.1038/s41409-020-0817-5
|
[25]
|
Issa, H., Sharma, N., Zhao, Q., et al. (2019) Comparison of Two Doses of Antithymocyte Globulin in Reduced-Intensity Conditioning Allogeneic Hematopoietic Stem Cell Transplanta-tion. Biology of Blood and Marrow Transplantation and Cellular Therapy, 25, 1993-2001. https://doi.org/10.1016/j.bbmt.2019.06.014
|
[26]
|
Bao, X., Zhu, Q., Xue, S., et al. (2016) Risk Factors of Clinically Refractory CMV Reactivation Following Allogeneic HSCT: A Single-Center Study in China. Bone Marrow Transplan-tation, 51, 1625-1627.
https://doi.org/10.1038/bmt.2016.231
|
[27]
|
吴亚妹, 曹永彬, 李晓红, 徐丽昕, 等. 膦甲酸钠预防及抢先治疗造血干细胞移植中巨细胞病毒感染的临床研究[J]. 白血病•淋巴瘤, 2017, 26(6): 331-335.
|
[28]
|
El Helou, G. and Razonable, R.R. (2019) Letermovir for the Prevention of Cytomegalovirus Infection and Disease in Transplant Recipients: An Evidence-Based Review. Infection and Drug Resistance, 12, 1481-1491.
https://doi.org/10.2147/IDR.S180908
|
[29]
|
Maertens, J., Cordonnier, C., Jaksch, P., et al. (2019) Maribavir for Preemptive Treatment of Cytomegalovirus Reactivation. New England Journal of Medicine, 381, 1136-1147. https://doi.org/10.1056/NEJMoa1714656
|
[30]
|
Avery, R.K., Alain, S., Alexander, B.D., et al. (2022) Maribavir for Refractory Cytomegalovirus Infections with or without Resistance Post-Transplant: Results from a Phase 3 Randomized Clinical Trial. Clinical Infectious Diseases, 75, 690-701. https://doi.org/10.1093/cid/ciab988
|
[31]
|
Frange, P. and Leruez-Ville, M. (2018) Maribavir, Brincidofovir and Letermovir: Efficacy and Safety of New Antiviral Drugs for Treating Cytomegalovirus Infections. Médecine et Maladies Infectieuses, 48, 495-502.
https://doi.org/10.1016/j.medmal.2018.03.006
|
[32]
|
桂瑞瑞, 李珍, 祖璎玲, 等. CMV-CTL治疗替代供者造血干细胞移植后复发难治性CMV感染17例疗效及安全性[J]. 中华血液学杂志, 2021, 42(10): 865-868.
|
[33]
|
王琪. 人巨细胞病毒亚单位疫苗的研究进展[J]. 国际生物制品学杂志, 2019, 42(3): 147-151.
|
[34]
|
中华医学会血液学分会, 中国医师协会血液科医师分会. 造血干细胞移植后EB病毒相关淋巴增殖性疾病中国专家共识(2022年版) [J]. 中华血液学杂志, 2022, 43(9): 716-725.
|
[35]
|
Lindsay, J., Othman, J., Heldman, M.R. and Slavin, M.A. (2021) Epstein-Barr virus Posttransplant Lymphoproliferative Disorder: Update on Management and Outcomes. Current Opin-ion in Infectious Diseases, 34, 635-645.
https://doi.org/10.1097/QCO.0000000000000787
|
[36]
|
Wang, Y., Fu, H.-X., Liu, D.-H., et al. (2014) Influence of Two Different Doses of Antithymocyte Globulin in Patients with Standard-Risk Disease Following Haploidentical Transplantation: A Randomized Trial. Bone Marrow Transplantation, 49, 426-433. https://doi.org/10.1038/bmt.2013.191
|
[37]
|
Styczynski, J., Van Der Velden, W., Fox, C.P., et al. (2016) Manage-ment of Epstein-Barr Virus Infections and Post-Transplant Lymphoproliferative Disorders in Patients after Allogeneic Hematopoietic Stem Cell Transplantation: Sixth European Conference on Infections in Leukemia (ECIL-6) Guidelines. Haematologica, 101, 803-811.
https://doi.org/10.3324/haematol.2016.144428
|
[38]
|
Curtis, R.E., Travis, L.B., Rowlings, P.A., Socié, G., Kingma, D.W., Banks, P.M., Jaffe, E.S., Sale, G.E., Horowitz, M.M., witherspoon, R.P., Shriner, D.A., Weisdorf, D.J., Kolb, H.-J., Sullivan, K.M., Sobocinski, K.A., Gale, R.P., Hoover, R.N., Fraumeni, J.F. and Deeg, H.J. (1999) Risk of Lym-phoproliferative Disorders after Bone Marrow Transplantation: A Multi-Institutional Study. Blood, 94, 2208-2216.
|
[39]
|
Liu, L., Liu, Q. and Feng, S. (2020) Management of Epstein-Barr Virus-Related Post-Transplant Lymphoproliferative Disorder after Allogeneic Hematopoietic Stem Cell Transplantation. Therapeutic Advances in He-matology, 11, Article ID: 2040620720910964. https://doi.org/10.1177/2040620720910964
|
[40]
|
Uhlin, M., Wikell, H., Sundin, M., et al. (2013) Risk Factors for Epstein-Barr Virus-Related Post-Transplant Lymphoproliferative Disease after Allogeneic Hematopoietic Stem Cell Transplantation. Haematologica, 99, 346-352.
https://doi.org/10.3324/haematol.2013.087338
|
[41]
|
Al Hamed, R., Bazarbachi, A.H. and Mohty, M. (2020) Ep-stein-Barr Virus-Related Post-Transplant Lymphoproliferative Disease (EBV-PTLD) in the Setting of Allogeneic Stem Cell Transplantation: A Comprehensive Review from Pathogenesis to Forthcoming Treatment Modalities. Bone Marrow Transplantation, 55, 25-39.
https://doi.org/10.1038/s41409-019-0548-7
|
[42]
|
Xu, L.-P., Zhang, C.-L., Mo, X.-D., et al. (2015) Epstein-Barr Virus-Related Post-Transplantation Lymphoproliferative Disorder after Unmanipulated Human Leukocyte Antigen Hap-loidentical Hematopoietic Stem Cell Transplantation: Incidence, Risk Factors, Treatment, and Clinical Outcomes. Trans-plantation and Cellular Therapy, 21, 2185-2191.
https://doi.org/10.1016/j.bbmt.2015.07.035
|
[43]
|
Zallio, F., Primon, V., Tamiazzo, S., et al. (2013) Epstein-Barr Virus Reactivation in Allogeneic Stem Cell Transplantation Is Highly Related to Cytomegalovirus Reactivation. Clinical Transplantation, 27, E491-E497.
https://doi.org/10.1111/ctr.12172
|
[44]
|
鲍协炳, 朱倩, 仇惠英, 等. 异基因造血干细胞移植后EBV感染临床危险因素分析[J]. 中华血液学杂志, 2016, 37(2): 138-143.
|
[45]
|
Hong, J., Ni, J., Ruan, M., et al. (2020) LMP1-Specific Cytotoxic T Cells for the Treatment of EBV-Related Post-Transplantation Lymphoproliferative Disorders. International Journal of Hematology, 111, 851-857.
https://doi.org/10.1007/s12185-020-02844-7
|
[46]
|
Prockop, S.E., Mahadeo, K.M., Beitinjaneh, A., et al. (2022) Multicenter, Open-Label, Phase 3 (P3) Study of Tabelecleucel (Tab-cel) for Solid Organ (SOT) or Allogeneic Hemato-poietic Cell Transplant (HCT) Recipients with Epstein-Barr Virus-Driven Post Transplant Lymphoproliferative Disease (EBV+ PTLD) after Failure of Rituximab (R) or Rituximab and Chemotherapy (R + C) (ALLELE). Transplantation and Cellular Therapy, 28, S22-S23.
https://doi.org/10.1016/S2666-6367(22)00184-1
|
[47]
|
牛燕燕, 董玉君, 尹玥, 等. 全血EB病毒DNA载量对异基因造血干细胞移植后淋巴增殖性疾病的诊断价值[J]. 中华血液学杂志, 2021, 42(11): 904-910.
|
[48]
|
许兰平, 黄晓军, 刘代红, 陈育红, 石红霞, 陈定宝. 造血干细胞移植后淋巴细胞增殖性疾病的临床研究[J]. 中华内科杂志, 2007, 46(12): 996-999.
|
[49]
|
Ru, Y., Zhang, X., Song, T., et al. (2020) Epstein-Barr Virus Reactivation after Allogeneic Hematopoietic Stem Cell Transplantation: Multifactorial Impact on Transplant Outcomes. Bone Marrow Transplantation, 55, 1754-1762.
https://doi.org/10.1038/s41409-020-0831-7
|
[50]
|
Wang, L.L.-W., Janes, M.E., Kumbhojkar, N., et al. (2021) Cell Therapies in the Clinic. Bioengineering & Translational Medicine, 6, e10214. https://doi.org/10.1002/btm2.10214
|